首页> 美国卫生研究院文献>International Journal of Nanomedicine >Hydroxypropyl-β-cyclodextrin functionalized calcium carbonate microparticles as a potential carrier for enhancing oral delivery of water-insoluble drugs
【2h】

Hydroxypropyl-β-cyclodextrin functionalized calcium carbonate microparticles as a potential carrier for enhancing oral delivery of water-insoluble drugs

机译:羟丙基-β-环糊精官能化的碳酸钙微粒可作为增强水不溶性药物口服递送的潜在载体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The objective of the present study was to demonstrate that a novel hydroxypropyl-β-cyclodextrin functionalized calcium carbonate (HP-β-CD/CC) based amorphous solid dispersion (ASD) can be used to increase the solubility and oral bioavailability of water-insoluble drugs. Irbesartan (IRB) was selected as a model compound and loaded into the nanoporous HP-β-CD/CC matrix using an immersion method. The IRB-loaded HP-β-CD/CC formulation was characterized by various analytical techniques, such as specific surface area analysis, scanning electron microscopy (SEM), dynamic light scattering (DLS), powder X-ray diffraction (PXRD), and differential scanning calorimetry (DSC). Analyses with PXRD and DSC confirmed that IRB was fully converted into the amorphous form in the nanopores of HP-β-CD/CC. From the solubility and dissolution tests, it was observed that the aqueous solubility and dissolution rate of IRB-loaded HP-β-CD/CC were increased significantly compared with those of pure IRB and IRB-loaded mesoporous silica. Likewise, the IRB-loaded HP-β-CD/CC formulation exhibited better absorption compared with that of the commercially available IRB capsules in beagle dogs. The mean peak plasma concentration (Cmax) and the area under the mean plasma concentration–time curve (AUC[0→48]) of IRB-loaded HP-β-CD/CC were 1.56- and 1.52-fold higher than that of the commercial product, respectively. Furthermore, the IRB-loaded HP-β-CD/CC formulation exhibited excellent stability against re-crystallization. These results clearly demonstrate that HP-β-CD/CC based porous ASD is a promising formulation approach to improve the aqueous solubility and the in vivo absorption performance of a water-insoluble compound like IRB.
机译:本研究的目的是证明基于羟基丙基-β-环糊精的新型碳酸钙(HP-β-CD/ CC)非晶态固体分散体(ASD)可用于提高水不溶性药物的溶解度和口服生物利用度毒品。选择厄贝沙坦(IRB)作为模型化合物,并使用浸没法将其加载到纳米多孔HP-β-CD/ CC基质中。装有IRB的HP-β-CD/ CC制剂通过多种分析技术进行了表征,例如比表面积分析,扫描电子显微镜(SEM),动态光散射(DLS),粉末X射线衍射(PXRD)和差示扫描量热法(DSC)。用PXRD和DSC进行的分析证实,IRB在HP-β-CD/ CC的纳米孔中已完全转化为无定形形式。通过溶解度和溶解度测试,观察到,与纯IRB和IRB中孔二氧化硅相比,IRB负载的HP-β-CD/ CC的水溶解度和溶解速率显着增加。同样,与比格犬中的市售IRB胶囊相比,负载IRB的HP-β-CD/ CC制剂表现出更好的吸收。装载IRB的HP-β-CD/ CC的平均血浆峰值浓度(Cmax)和平均血浆浓度-时间曲线下的面积(AUC [0→48])分别比其高1.56倍和1.52倍。商业产品。此外,负载IRB的HP-β-CD/ CC制剂具有出色的抗重结晶稳定性。这些结果清楚地表明,基于HP-β-CD/ CC的多孔ASD是一种有前途的配制方法,可以改善水不溶性化合物(如IRB)的水溶性和体内吸收性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号